PRESS RELEASES

HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial

HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s investigational first-in-class antibody ICT01 activating gamma delta (γδT) cells

HalioDx, the immuno-oncology diagnostic company, announced a collaboration with ImCheck Therapeutics, a biotech company developing a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases. HalioDx will work with ImCheck to generate tumor immune contexture information, which is determined by the density, composition, functional state and organization of immune infiltration into the tumor, for patients enrolled in EVICTION, the first-in-human clinical trial of ICT01. ICT01 is a humanized monoclonal antibody that activates γ9δ2 T cells, part of the innate immune system that is responsible for immunosurveillance for malignancy and infection,  by targeting BTN3A, a unique target expressed in several solid and hematologic tumors.

“ICT01 is a novel immunotherapy with an exciting and innovative mechanism of action that includes a potentially strong impact on the immune contexture of tumors, therefore our trial, which has continued to enroll and treat patients despite the current pandemic, requires a partner with expertise like HalioDx," stated Pierre d’Epenoux, Chief Executive Officer at ImCheck Therapeutics.

“We are delighted to support ImCheck Therapeutics in this translational effort for its first-in-human EVICTION trial, leveraging our unique expertise to analyze immune contexture, in particular with our Immunoscore® technologies,”said Vincent Fert, CEO of HalioDx. ”ImCheck Therapeutics is a promising biotech company within the Marseille Immunopole cluster and this collaboration underscores the innovation and scientific strength of our ecosystem.”